Innorna Announces U.S. FDA RPDD Granted to IN016 for the Treatment of Progressive Familial Intrahepatic Cholestasis
UNITED STATES, July 13, 2024 /EINPresswire.com/ -- Innorna, a clinical-stage biotech company pioneering its proprietary lipid nanoparticle (LNP) technology to develop novel RNA therapeutics, today announced that the U.S. Food and Drug …